Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Neurocrine Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Neurocrine Biosciences, Inc.’s stock price such as:

• Neurocrine Biosciences, Inc.’s current stock price and volume
• Why Neurocrine Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for NBIX from analysts
• NBIX’s stock price momentum as measured by its relative strength

About Neurocrine Biosciences, Inc. (NBIX)

Before we jump into Neurocrine Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Want to learn more about Neurocrine Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Neurocrine Biosciences, Inc..

Neurocrine Biosciences, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Neurocrine Biosciences, Inc.’s stock price was $166.800.

Neurocrine Biosciences, Inc. is down 10.08% from its previous closing price of $185.500.

During the last market session, Neurocrine Biosciences, Inc.’s stock traded between $164.560 and $185.550. Currently, there are approximately 100.50 million shares outstanding for Neurocrine Biosciences, Inc..

Neurocrine Biosciences, Inc.’s price-earnings (P/E) ratio is currently at 25.6, which is high compared to the Biotechnology industry median of 19. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Neurocrine Biosciences, Inc. Stock Price History

Neurocrine Biosciences, Inc.’s (NBIX) price is currently down 1.03% so far this month.

During the month of July, Neurocrine Biosciences, Inc.’s stock price has reached a high of $186.120 and a low of $164.560.

Over the last year, Neurocrine Biosciences, Inc. has hit prices as high as $186.120 and as low as $122.138. Year to date, Neurocrine Biosciences, Inc.’s stock is up 17.61%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Neurocrine Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Neurocrine Biosciences, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Neurocrine Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Neurocrine Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Neurocrine Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Neurocrine Biosciences, Inc. (NBIX) by visiting AAII Stock Evaluator.

Relative Price Strength of Neurocrine Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Neurocrine Biosciences, Inc. has a weighted four-quarter relative price strength of 6.77%, which translates to a Momentum Score of 75 and is considered to be Strong.

Want to learn more about how Neurocrine Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Neurocrine Biosciences, Inc. Stock Price: Bottom Line

As of July 31, 2026, Neurocrine Biosciences, Inc.’s stock price is $166.800, which is down 10.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Neurocrine Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.